Rainbow BioSci seeks to develop treatment for traumatic brain injury
USA-based Rainbow BioSciences, the biotech subsidiary of Rainbow Coral Corp (OTCBB: RBCC) revealed yesterday that it is continuing due diligence toward an agreement to help develop a promising new treatment for traumatic brain injury (TBI), as concern continues to grow over the troubling incidence of TBI among athletes and soldiers.
Currently, TBI and other neuropathic maladies can only be diagnosed after death, leaving many soldiers and athletes to wonder if they have it or not. RBCC hopes to help change that.
The company is now negotiating a potential joint venture with Amarantus BioSciences (OTCBB AMBS), a biotech firm that has developed a therapeutic protein known as MANF to treat disorders associated with endoplasmic reticulum stress, including traumatic brain injury.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze